ريپاݘلينيد تيڤع ١ ملغ إسرائيل - العربية - Ministry of Health

ريپاݘلينيد تيڤع ١ ملغ

teva pharmaceutical indust.ltd - repaglinide 1 mg - tablets - repaglinide - treatment of type ii diabetes.

ألفا D3 ٠.٢٥ مكغ كبسولات إسرائيل - العربية - Ministry of Health

ألفا d3 ٠.٢٥ مكغ كبسولات

teva pharmaceutical indust.ltd - alfacalcidol 0.25 mcg - capsules soft gelatin - alfacalcidol - renal bone disease (renal osteodystrophy), hypoparathyroidism, hyperparathyroidism (with bone disease) - primary and tertiary. neonatal hypocalcemia, rickets and osteomalacia, osteoporosis.

ألفا D3 ١.٠ مكغ كبسولات إسرائيل - العربية - Ministry of Health

ألفا d3 ١.٠ مكغ كبسولات

teva pharmaceutical indust.ltd - alfacalcidol 1 mcg - capsules soft gelatin - alfacalcidol - renal bone disease (renal osteodystrophy), hypoparathyroidism, hyperparathyroidism (with bone disease) - primary and tertiary. neonatal hypocalcemia, rickets and osteomalacia, osteoporosis.

ﺳپيرونولاكتون تيڤع ١٠٠ ملغ إسرائيل - العربية - Ministry of Health

ﺳپيرونولاكتون تيڤع ١٠٠ ملغ

teva pharmaceutical indust.ltd - spironolactone 100 mg - tablets - spironolactone - edematous conditions: congestive heart failure; cirrosis of the liver accompanied by edema and/or ascites nephrotic syndrome. essential hypertention. primary hyperaldostronism. hypokalemia.

پنيﺪيل ١٠ ملغ أقراص ذات مفعول ممتد إسرائيل - العربية - Ministry of Health

پنيﺪيل ١٠ ملغ أقراص ذات مفعول ممتد

teva pharmaceutical indust.ltd - felodipine 10 mg - tablets extended release - felodipine - moderate to severe hypertension. angina pectoris.

پنيﺪيل ٢.٥ ملغ أقراص ذات مفعول ممتد إسرائيل - العربية - Ministry of Health

پنيﺪيل ٢.٥ ملغ أقراص ذات مفعول ممتد

teva pharmaceutical indust.ltd - felodipine 2.5 mg - tablets extended release - felodipine - hypertension. angina pectoris.

راﻣيپريل تيڤع ٥ ملغ إسرائيل - العربية - Ministry of Health

راﻣيپريل تيڤع ٥ ملغ

teva pharmaceutical indust.ltd - ramipril 5 mg - tablets - ramipril - - hypertension - congestive heart failure - reduction of mortality in patients after mi with left ventricular dysfunction for reducing the risk of myocardial infarction stoke cardiovascular death or need for revascularization procedures in patients over 55 years or more who have clinical evidence of cardiovascular disease (previous mi unstable angina or multivessel cabg or multivessel ptca) stroke or peripheral vascular disease. also for reducing the risk of myocardial infarction stroke cardiovascular death or need for revascularization procedures in diabetic patients of 55 years or more who have one or more of the following clinical findings : hypertension (systolic blood pressure > 160 mmhg or diastolic pressure > 90 mmhg) high total cholesterol (>5.2 mmol/l) low hdl ( <0.9 mmol/l) current smoker known microalbuminuria clinical evidence of previous vascular disease. - prevention of progressive renal failure in patients with persistent proteinuria in excess of 1g/day.